Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease
Authors:
- Miguel Díaz-HernándezMiguel Díaz-Hernández
- Jesús Torres-PerazaJTJesús Torres-Peraza
- María A. MoránMMMaría A. Morán
- Pilar Gómez-RamosPGPilar Gómez-Ramos
- Jordi AlberchJAJordi Alberch
- José J. LucasJLJosé J. Lucas
Open Access
- 19 October 2005
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 25 (42) , 9773-9781
Abstract
The primary mechanism responsible for Huntington's disease remains unknown. Postulated early pathogenic events include the following: impaired protein folding, altered protein degradation, mitochondrial dysfunction, and transcriptional dysregulation. Although related therapies can delay disease progression in mouse models, they target downstream and probably indirect effects of mutant-huntingtin expression. Accordingly, in case they prove beneficial in humans, they might only palliate some aspects of disease. Our previous studies in the Tet/HD94 conditional model and the recently reported efficacy of RNA interference against mutant huntingtin in another mouse model support silencing mutant-huntingtin expression as a valid therapeutic approach that has the advantage of targeting toxicity at its root. Here, we address whether gene silencing can still be beneficial in the late stages of disease with detectable striatal neuron loss. Stereological analysis was applied to determine an age at which Tet/HD94 mice show a decrease in the number of striatal neurons. Then, progression of neuropathology and motor phenotype were analyzed in mice that were allowed to continue expressing mutant huntingtin and in mice that no longer expressed it. Neuronal loss did not revert in gene-off mice, but the additional loss that takes place in gene-on mice was prevented. The total number of huntingtin-containing inclusions dramatically reverted, but a small fraction of inclusions positive for the amyloid dye thioflavin-S remained. Interestingly, despite a 20% decrease in striatal neurons and the presence of amyloid-like irreversible inclusions, gene-off mice fully recover from their motor deficit, thus ruling out amyloid-like huntingtin inclusions as the main toxic species and suggesting that gene-silencing therapies might work in late stages of disease.Keywords
This publication has 46 references indexed in Scilit:
- Tau Suppression in a Neurodegenerative Mouse Model Improves Memory FunctionScience, 2005
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's DiseaseJournal of Neuroscience, 2004
- RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxiaNature Medicine, 2004
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004
- Decreased hippocampal cell proliferation in R6/1 Huntington’s miceNeuroReport, 2004
- Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activityJournal of Cell Biology, 2003
- Early Degenerative Changes in Transgenic Mice Expressing Mutant Huntingtin Involve Dendritic Abnormalities but No Impairment of Mitochondrial Energy ProductionExperimental Neurology, 2001
- More hippocampal neurons in adult mice living in an enriched environmentNature, 1997
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993